William Blair Investment Management LLC Sells 31,987 Shares of ANI Pharmaceuticals, Inc. $ANIP

William Blair Investment Management LLC lessened its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 9.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 316,693 shares of the specialty pharmaceutical company’s stock after selling 31,987 shares during the period. William Blair Investment Management LLC owned 1.41% of ANI Pharmaceuticals worth $25,000,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Hantz Financial Services Inc. raised its position in ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 237 shares during the last quarter. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. State of Wyoming bought a new position in ANI Pharmaceuticals in the 2nd quarter worth approximately $50,000. Federated Hermes Inc. bought a new position in ANI Pharmaceuticals in the 3rd quarter worth approximately $93,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in ANI Pharmaceuticals by 30.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock worth $86,000 after purchasing an additional 253 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Insider Buying and Selling

In other news, insider Christopher Mutz sold 3,162 shares of the business’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $71.64, for a total value of $226,525.68. Following the completion of the transaction, the insider owned 91,309 shares of the company’s stock, valued at $6,541,376.76. The trade was a 3.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Nikhil Lalwani sold 55,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the completion of the transaction, the chief executive officer directly owned 349,889 shares of the company’s stock, valued at $27,140,889.73. This trade represents a 13.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 91,427 shares of company stock worth $7,089,066 over the last ninety days. Insiders own 8.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on ANIP shares. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Five research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Price Performance

ANIP opened at $82.72 on Tuesday. The company has a fifty day moving average price of $78.10 and a two-hundred day moving average price of $79.93. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. ANI Pharmaceuticals, Inc. has a 52 week low of $56.71 and a 52 week high of $99.50. The firm has a market capitalization of $1.88 billion, a PE ratio of 20.94 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same quarter in the previous year, the business earned $1.70 EPS. The business’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.